Back to resultsTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
Primary Purpose
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Palbociclib
Sunitinib
Temsirolimus
Trastuzumab and Pertuzumab
Vemurafenib and Cobimetinib
Regorafenib
Olaparib
Pembrolizumab
Nivolumab and Ipilimumab
Abemaciclib
Talazoparib
Atezolizumab and PHESGO
Atezolizumab and Talazoparib
Entrectinib
Larotrectinib
Tucatinib plus Trastuzumab Subcutaneous (SC)
Futibatinib
Sponsored by
About this trial
This is an interventional treatment trial for Lymphoma, Non-Hodgkin focused on measuring cancer, off-label, precision medicine, targeted therapy
Eligibility Criteria
Inclusion Criteria:
- 12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
- Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
- Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1.5 x 106/µl
- Hemoglobin > 9.0 g/dl
- Platelets > 75,000/µl
- Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
- Patients must have disease that can be objectively measured by physicial or radiographic exam or evaluable disease (per RECIST v1.1 for solid tumor, Lugano criteria for non Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral computed tomography (CT) scan, Magnetic Resonance Imaging (MRI), or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patients who have assessable disease by physical or radiographic examination but do not meet these definitions of measurable disease are eligible and will be considered to have evaluable disease. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible.
- Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
- Ability to understand and the willingness to sign a written informed consent/assent document.
- Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
- For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
- Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
- Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
- Patients with primary brain tumors or leptomeningeal metastases are excluded.
- Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
- Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Sites / Locations
- University of Alabama at Birmingham Comprehensive Cancer CenterRecruiting
- Cancer Treatment Centers of America-PhoenixRecruiting
- Sutter AuburnRecruiting
- Sutter Alta BatesRecruiting
- The Angeles Clinic and Research Institute, A Cedars-Sinai AffiliateRecruiting
- Kaiser Permanente - Oakland Medical CenterRecruiting
- Sutter Palo Alto Medical Foundation: Palo AltoRecruiting
- Kaiser Permanente - Roseville Medical CenterRecruiting
- Sutter RosevilleRecruiting
- Kaiser Permanente - Sacramento Medical CenterRecruiting
- Sutter SacramentoRecruiting
- Kaiser Permanente - South San Francisco Medical CenterRecruiting
- California Pacific Medical Center Research InstituteRecruiting
- Kaiser Permanente - San Francisco Medical CenterRecruiting
- Sutter Cancer Research ConsortiumRecruiting
- Kaiser Permanente - San Jose Medical CenterRecruiting
- Kaiser Permanente - San Leandro Medical CenterRecruiting
- Kaiser Permanente - Santa Clara Medical CenterRecruiting
- Sutter Palo Alto Medical Foundation: Santa CruzRecruiting
- Sutter Palo Alto Medical Foundation: FremontRecruiting
- Sutter Palo Alto Medical Foundation: SunnyvaleRecruiting
- Kaiser Permanente - Vallejo Medical CenterRecruiting
- Kaiser Permanente - Walnut Creek Medical CenterRecruiting
- Saint Vincent's Medical Center (SVMC)Recruiting
- Hartford HospitalRecruiting
- Midstate Medical Center (MSMC)Recruiting
- The Hospital of Central Connecticut (HOCC) Cancer CenterRecruiting
- William W. Backus HospitalRecruiting
- Charlotte HungerfordRecruiting
- Windham Hospital (WH)Recruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists East / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists Panhandle / Sarah Cannon Research InstituteRecruiting
- Holy Cross HospitalRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- University of Florida HealthRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- University of Miami Sylvester Comprehensive Cancer CenterRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists East / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists Panhandle / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists South / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists East / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists East / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists East / Sarah Cannon Research InstituteRecruiting
- Florida Cancer Specialists North / Sarah Cannon Research InstituteRecruiting
- Cancer Treatment Centers of America - AtlantaRecruiting
- Emory University Winship Cancer InstituteRecruiting
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research PavilionRecruiting
- Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma InstituteRecruiting
- Lewis Cancer & Research PavilionRecruiting
- Summit Cancer CareRecruiting
- The Queen's Medical Center (The University of Texas MD Anderson Cancer Center)
- Cancer Treatment Centers of America-ChicagoRecruiting
- Community Health Network (The University of Texas MD Anderson Cancer Center)Recruiting
- Harold Alfond Center for Cancer CareRecruiting
- Jackson Laboratory - Maine Cancer Genomics InitiativeRecruiting
- Waldo County General HospitalRecruiting
- SMHC Cancer Care and Blood Disorders -BiddefordRecruiting
- Northern Light Cancer CareRecruiting
- Raish Peavey Haskell Children's Cancer and Treatment CenterRecruiting
- MaineHealth Cancer Care -BrunswickRecruiting
- New England Cancer SpecialistRecruiting
- York Hopsital Oncology & Infusion Care in KitteryRecruiting
- Stephens Memorial HospitalRecruiting
- Penobscot Bay Medical CenterRecruiting
- SMHC Cancer Care and Blood Disorders -SandfordRecruiting
- Maine Children's Cancer ProgramRecruiting
- Maine Medical Partner's Women's HealthRecruiting
- New England Cancer SpecialistRecruiting
- MaineHealth Cancer Care -South PortlandRecruiting
- New England Cancer SpecialistRecruiting
- York Hospital Oncology & Infusion Care in WellsRecruiting
- York Hospital Oncology & Infusion Care in YorkRecruiting
- Trinity Health Ann Arbor HospitalRecruiting
- University of MichiganRecruiting
- Ascension St. John HospitalRecruiting
- Genesys Hurley Cancer InstituteRecruiting
- Cancer Research Consortium of West MichiganRecruiting
- Sparrow HospitalRecruiting
- Trinity Health Livonia HospitalRecruiting
- Trinity Health Oakland HospitalRecruiting
- Ascension St. Mary's HospitalRecruiting
- Michigan Cancer Research ConsortiumRecruiting
- St. John Macomb Oakland HospitalRecruiting
- University of Nebraska Medical CenterRecruiting
- NH Oncology - Hematology, PARecruiting
- Solinsky Center for Cancer CareRecruiting
- New England Cancer SpecialistRecruiting
- Lovelace Medical Center - Saint Joseph SquareRecruiting
- Presbyterian Kaseman HospitalRecruiting
- The University of New Mexico Comprehensive Cancer CenterRecruiting
- Memorial Medical CenterRecruiting
- Presbyterian Rust Medical CenterRecruiting
- Northwell Health Monter Cancer CenterRecruiting
- Cohen Children's Medical CenterRecruiting
- Herbert Irving Comprehensive Cancer CenterRecruiting
- Manhattan Eye, Ear, and Throat HospitalRecruiting
- Phelps HospitalRecruiting
- Lineberger Comprehensive Cancer CenterRecruiting
- Atrium Health's Levine Cancer InstituteRecruiting
- Sanford Health- BismarckRecruiting
- Sanford Health- FargoRecruiting
- University of Cincinnati Medical CenterRecruiting
- Kettering HealthRecruiting
- West Chester HospitalRecruiting
- Providence Health & ServicesRecruiting
- Lehigh Valley Health NetworkRecruiting
- Lehigh Valley Hospital- MuhlenbergRecruiting
- Pocono Medical CenterRecruiting
- Lehigh Valley Hospital-HazletonRecruiting
- Fox Chase Cancer CenterRecruiting
- SC Cancer Specialists at St. Joseph's/Candler BlufftonRecruiting
- St. Joseph's/Candler SmithRecruiting
- Summit Cancer Care at St. Josph's/Candler BlufftonRecruiting
- South Carolina Cancer SpecialistsRecruiting
- Sanford Cancer Center Oncology Clinic and PharmacyRecruiting
- Tennessee Oncology - Nashville / Sarah Cannon Research InstituteRecruiting
- The University of Texas MD Anderson Cancer CenterRecruiting
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer CenterRecruiting
- Dixie Regional Medical Center-River Road CampusRecruiting
- Intermountain HealthcareRecruiting
- Inova Schar Cancer InstituteRecruiting
- Swedish Cancer InstituteRecruiting
- Aurora Cancer Care - BurlingtonRecruiting
- Aurora Health Care - Germantown Health CenterRecruiting
- Aurora Cancer Care - GraftonRecruiting
- Aurora BayCare Medical CenterRecruiting
- Aurora Cancer Care - Kenosha SouthRecruiting
- Aurora Bay Area Medical CenterRecruiting
- Aurora Cancer Care MilwaukeeRecruiting
- Aurora St. Luke's Medical CenterRecruiting
- Aurora Sinai Medical CenterRecruiting
- Aurora West Allis Medical CenterRecruiting
- Vince Lombardi Cancer Clinic - OshkoshRecruiting
- Aurora Cancer Care - RacineRecruiting
- Vince Lombardi Cancer CenterRecruiting
- Aurora Medical Center in SummitRecruiting
- Vince Lombardi Cancer Clinic - Two RiversRecruiting
- Aurora Cancer Care - Milwaukee WestRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Arm 13
Arm 14
Arm 15
Arm 16
Arm 17
Arm Type
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Other
Arm Label
Group 4 (CDKN2A, CDK4, CDK6)
Group 5 (CSF1R,PDGFR,VEGFR)
Group 6 (mTOR, TSC)
Group 8 (ERBB2)
Group 9 (BRAF V600E/D/K/R)
Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)
Group 14 (BRCA1/2; ATM)
Group 15 (POLE, POLD1)
Group 16 (MSI-H, high mutational load and others)
Group 17 (CDKN2A, CDK4, CDK6)
Group 19 (BRCA1/2, PALB2)
Group 20 (ERBB2)
Group 21 (BRCA1/2, PALB2, ATM, and others)
Group 22 (ROS1 fusion)
Group 23 (NTRK amplification)
Group 24 (ERBB2)
Group 25
Arm Description
Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations
Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations
Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions
Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations
Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval
Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion
Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation
Outcomes
Primary Outcome Measures
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.
Secondary Outcome Measures
Overall survival (OS)
OS will be estimated using the Kaplan-Meier method
Full Information
NCT ID
NCT02693535
First Posted
February 11, 2016
Last Updated
September 29, 2023
Sponsor
American Society of Clinical Oncology
Collaborators
AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02693535
Brief Title
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Acronym
TAPUR
Official Title
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 14, 2016 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
American Society of Clinical Oncology
Collaborators
AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
******************************************************************************************************************************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
******************************************************************************************************************************************************************************
Detailed Description
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Keywords
cancer, off-label, precision medicine, targeted therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
3791 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group 4 (CDKN2A, CDK4, CDK6)
Arm Type
Other
Arm Description
Participants receive palbociclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Arm Title
Group 5 (CSF1R,PDGFR,VEGFR)
Arm Type
Other
Arm Description
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations
Arm Title
Group 6 (mTOR, TSC)
Arm Type
Other
Arm Description
Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations
Arm Title
Group 8 (ERBB2)
Arm Type
Other
Arm Description
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Arm Title
Group 9 (BRAF V600E/D/K/R)
Arm Type
Other
Arm Description
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations
Arm Title
Group 13 (RET,VEGFR1/2/3,KIT,PDGFRβ,RAF-1,BRAF)
Arm Type
Other
Arm Description
Participants receive regorafenib - dosage, frequency and duration per label; acceptable genomic matches include RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF mutations or amplifications
Arm Title
Group 14 (BRCA1/2; ATM)
Arm Type
Other
Arm Description
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions
Arm Title
Group 15 (POLE, POLD1)
Arm Type
Other
Arm Description
Participants receive pembrolizumab - dosage, frequency and duration per label; acceptable genomic matches include specific POLE and POLD1 mutations
Arm Title
Group 16 (MSI-H, high mutational load and others)
Arm Type
Other
Arm Description
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations
Arm Title
Group 17 (CDKN2A, CDK4, CDK6)
Arm Type
Other
Arm Description
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Arm Title
Group 19 (BRCA1/2, PALB2)
Arm Type
Other
Arm Description
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations
Arm Title
Group 20 (ERBB2)
Arm Type
Other
Arm Description
Participants receive atezolizumab plus PHESGO - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression
Arm Title
Group 21 (BRCA1/2, PALB2, ATM, and others)
Arm Type
Other
Arm Description
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval
Arm Title
Group 22 (ROS1 fusion)
Arm Type
Other
Arm Description
Participants receive entrectinib - dosage, frequency and duration per label; acceptable genomic matches include any ROS1 fusion
Arm Title
Group 23 (NTRK amplification)
Arm Type
Other
Arm Description
Participants receive larotrectinib - dosage, frequency and duration per label; acceptable genomic matches include NTRK1/2/3 amplification
Arm Title
Group 24 (ERBB2)
Arm Type
Other
Arm Description
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Arm Title
Group 25
Arm Type
Other
Arm Description
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation
Intervention Type
Drug
Intervention Name(s)
Palbociclib
Other Intervention Name(s)
Ibrance
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Sunitinib
Other Intervention Name(s)
Sutent
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Temsirolimus
Other Intervention Name(s)
Torisel
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Trastuzumab and Pertuzumab
Other Intervention Name(s)
Herceptin and Perjeta
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Vemurafenib and Cobimetinib
Other Intervention Name(s)
Zelboraf and Cotellic
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Regorafenib
Other Intervention Name(s)
Stivarga
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Olaparib
Other Intervention Name(s)
Lynparza
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
Keytruda
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Nivolumab and Ipilimumab
Other Intervention Name(s)
Opdivo and Yervoy
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Abemaciclib
Other Intervention Name(s)
Verzenio
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Talazoparib
Other Intervention Name(s)
Talzenna
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Atezolizumab and PHESGO
Other Intervention Name(s)
Tecentriq and PHESGO
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Atezolizumab and Talazoparib
Other Intervention Name(s)
Tecentriq and Talzenna
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Entrectinib
Other Intervention Name(s)
Rozlytrek
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Larotrectinib
Other Intervention Name(s)
Vitrakvi
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Tucatinib plus Trastuzumab Subcutaneous (SC)
Other Intervention Name(s)
Tukysa and Herceptin Hylecta
Intervention Description
drug
Intervention Type
Drug
Intervention Name(s)
Futibatinib
Other Intervention Name(s)
Lytgobi
Intervention Description
drug
Primary Outcome Measure Information:
Title
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Description
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.
Time Frame
Assessed at 16 weeks of treatment
Secondary Outcome Measure Information:
Title
Overall survival (OS)
Description
OS will be estimated using the Kaplan-Meier method
Time Frame
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
Absolute neutrophil count ≥ 1.5 x 106/µl
Hemoglobin > 9.0 g/dl
Platelets > 75,000/µl
Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
Patients must have disease that can be objectively measured by physical or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible.
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
Ability to understand and the willingness to sign a written informed consent/assent document.
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
Patients with primary brain tumors or leptomeningeal metastases are excluded.
Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pam Mangat, MS
Phone
www.tapur.org
Email
tapur@asco.org
Facility Information:
Facility Name
University of Alabama at Birmingham Comprehensive Cancer Center
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Misty Lowery
Phone
205-644-2573
Email
mmlowery@uabmc.edu
First Name & Middle Initial & Last Name & Degree
Mehmet Akce, MD
Facility Name
Cancer Treatment Centers of America-Phoenix
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85338
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Russell Fernandez
Phone
623-207-3126
Email
russell.fernandez@ctca-hope.com
First Name & Middle Initial & Last Name & Degree
Robert Galamaga, DO
Facility Name
Sutter Auburn
City
Auburn
State/Province
California
ZIP/Postal Code
95602
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kirsten Babski
Phone
916-878-4990
Email
BabskiK@sutterhealth.org
First Name & Middle Initial & Last Name & Degree
Deepti Behl, MD
Facility Name
Sutter Alta Bates
City
Berkeley
State/Province
California
ZIP/Postal Code
94705
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher Tang
Phone
510-204-3428
Email
Christopher.Tang@sutterhealth.org
First Name & Middle Initial & Last Name & Degree
Deepti Behl, MD
Facility Name
The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Saba Mukarram
Phone
310-231-2181
Email
smukarram@theangelesclinic.org
First Name & Middle Initial & Last Name & Degree
Omid Hamid, MD
Facility Name
Kaiser Permanente - Oakland Medical Center
City
Oakland
State/Province
California
ZIP/Postal Code
94611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
Sutter Palo Alto Medical Foundation: Palo Alto
City
Palo Alto
State/Province
California
ZIP/Postal Code
94301
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
clinicaltrials@pamf.org
Facility Name
Kaiser Permanente - Roseville Medical Center
City
Roseville
State/Province
California
ZIP/Postal Code
95661
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
Sutter Roseville
City
Roseville
State/Province
California
ZIP/Postal Code
95661
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kirsten Babski
Phone
916-878-4990
Email
BabskiK@sutterhealth.org
First Name & Middle Initial & Last Name & Degree
Deepti Behl, MD
Facility Name
Kaiser Permanente - Sacramento Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95814
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
Sutter Sacramento
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
SIMR@sutterhealth.org
First Name & Middle Initial & Last Name & Degree
Deepti Behl, MD
Facility Name
Kaiser Permanente - South San Francisco Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94080
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
California Pacific Medical Center Research Institute
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
415-600-1654
Email
clinicalresearch@sutterhealth.org
First Name & Middle Initial & Last Name & Degree
Deepti Behl, MD
Facility Name
Kaiser Permanente - San Francisco Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
Sutter Cancer Research Consortium
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurel Brechtel
Phone
415-600-1654
Email
BrechtLa@cpmcri.org
First Name & Middle Initial & Last Name & Degree
Stacy D'Andre, MD
Facility Name
Kaiser Permanente - San Jose Medical Center
City
San Jose
State/Province
California
ZIP/Postal Code
95119
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
Kaiser Permanente - San Leandro Medical Center
City
San Leandro
State/Province
California
ZIP/Postal Code
94577
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
Kaiser Permanente - Santa Clara Medical Center
City
Santa Clara
State/Province
California
ZIP/Postal Code
95051
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
Sutter Palo Alto Medical Foundation: Santa Cruz
City
Santa Cruz
State/Province
California
ZIP/Postal Code
95065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
clinicaltrials@pamf.org
Facility Name
Sutter Palo Alto Medical Foundation: Fremont
City
Santa Cruz
State/Province
California
ZIP/Postal Code
994538
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
clinicaltrials@pamf.org
Facility Name
Sutter Palo Alto Medical Foundation: Sunnyvale
City
Sunnyvale
State/Province
California
ZIP/Postal Code
94086
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
clinicaltrials@pamf.org
Facility Name
Kaiser Permanente - Vallejo Medical Center
City
Vallejo
State/Province
California
ZIP/Postal Code
94589
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M. Suga, MD
Facility Name
Kaiser Permanente - Walnut Creek Medical Center
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94596
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Desiree Goldstein
Email
desiree.goldstein@kp.org
First Name & Middle Initial & Last Name & Degree
Jennifer M Suga, MD
Facility Name
Saint Vincent's Medical Center (SVMC)
City
Bridgeport
State/Province
Connecticut
ZIP/Postal Code
06606
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
860-972-4700
Email
CancerResearchSupport@hhchealth.org
First Name & Middle Initial & Last Name & Degree
Wylie Hosmer, MD
Facility Name
Hartford Hospital
City
Hartford
State/Province
Connecticut
ZIP/Postal Code
06102
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
860-972-4700
Email
CancerResearchSupport@hhchealth.org
First Name & Middle Initial & Last Name & Degree
Wylie Hosmer, MD
Facility Name
Midstate Medical Center (MSMC)
City
Meriden
State/Province
Connecticut
ZIP/Postal Code
06451
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
860-972-4700
Email
CancerResearchSupport@hhchealth.org
First Name & Middle Initial & Last Name & Degree
Wylie Hosmer, MD
Facility Name
The Hospital of Central Connecticut (HOCC) Cancer Center
City
New Britain
State/Province
Connecticut
ZIP/Postal Code
06053
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
860-972-4700
Email
CancerResearchSupport@hhchealth.org
First Name & Middle Initial & Last Name & Degree
Wylie Hosmer, MD
Facility Name
William W. Backus Hospital
City
Norwich
State/Province
Connecticut
ZIP/Postal Code
06360
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
860-972-4700
Email
CancerResearchSupport@hhchealth.org
First Name & Middle Initial & Last Name & Degree
Wylie Hosmer, MD
Facility Name
Charlotte Hungerford
City
Torrington
State/Province
Connecticut
ZIP/Postal Code
06790
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
860-972-4700
Email
CancerResearchSupport@hhchealth.org
First Name & Middle Initial & Last Name & Degree
Wylie Hosmer, MD
Facility Name
Windham Hospital (WH)
City
Willimantic
State/Province
Connecticut
ZIP/Postal Code
06226
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
860-972-4700
Email
CancerResearchSupport@hhchealth.org
First Name & Middle Initial & Last Name & Degree
Wylie Hosmer, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Altamonte Springs
State/Province
Florida
ZIP/Postal Code
32701
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Bonita Springs
State/Province
Florida
ZIP/Postal Code
34135
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Bradenton
State/Province
Florida
ZIP/Postal Code
34211
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Brandon
State/Province
Florida
ZIP/Postal Code
33511
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Cape Coral
State/Province
Florida
ZIP/Postal Code
33909
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33761
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists East / Sarah Cannon Research Institute
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32117
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Schachar Peles, MD
Facility Name
Florida Cancer Specialists Panhandle / Sarah Cannon Research Institute
City
Fleming Island
State/Province
Florida
ZIP/Postal Code
32003
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Viralkumar Bhanderi, MD
Facility Name
Holy Cross Hospital
City
Fort Lauderdale
State/Province
Florida
ZIP/Postal Code
33308
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-3671
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Zdenka Segota, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33905
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florida
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33908
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32605
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
University of Florida Health
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nghi Lam, MS
Phone
352-265-5329
Email
Nghi.Lam@cancer.ufl.edu
First Name & Middle Initial & Last Name & Degree
Thomas George, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Largo
State/Province
Florida
ZIP/Postal Code
33770
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Lecanto
State/Province
Florida
ZIP/Postal Code
34461
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
University of Miami Sylvester Comprehensive Cancer Center
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carolina Troche, BS
Phone
305-243-1481
Email
cxt582@med.miami.edu
First Name & Middle Initial & Last Name & Degree
Carmen Calfa, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Naples
State/Province
Florida
ZIP/Postal Code
34102
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Ocala
State/Province
Florida
ZIP/Postal Code
34474
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Orange City
State/Province
Florida
ZIP/Postal Code
32763
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Port Charlotte
State/Province
Florida
ZIP/Postal Code
33980
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34236
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists East / Sarah Cannon Research Institute
City
Stuart
State/Province
Florida
ZIP/Postal Code
34994
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Schachar Peles, MD
Facility Name
Florida Cancer Specialists Panhandle / Sarah Cannon Research Institute
City
Tallahassee
State/Province
Florida
ZIP/Postal Code
32308
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Viralkumar Bhanderi, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Tavares
State/Province
Florida
ZIP/Postal Code
32778
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
The Villages
State/Province
Florida
ZIP/Postal Code
32159
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Trinity
State/Province
Florida
ZIP/Postal Code
34655
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Venice
State/Province
Florida
ZIP/Postal Code
34285
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists South / Sarah Cannon Research Institute
City
Venice
State/Province
Florida
ZIP/Postal Code
34292
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Fadi Kayali, MD
Facility Name
Florida Cancer Specialists East / Sarah Cannon Research Institute
City
Vero Beach
State/Province
Florida
ZIP/Postal Code
32960
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Schachar Peles, MD
Facility Name
Florida Cancer Specialists East / Sarah Cannon Research Institute
City
Wellington
State/Province
Florida
ZIP/Postal Code
33414
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Schachar Peles, MD
Facility Name
Florida Cancer Specialists East / Sarah Cannon Research Institute
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
Shachar Peles, MD
Facility Name
Florida Cancer Specialists North / Sarah Cannon Research Institute
City
Winter Park
State/Province
Florida
ZIP/Postal Code
32789
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Email
ClinicalTrials@flcancer.com
First Name & Middle Initial & Last Name & Degree
David Wright, MD
Facility Name
Cancer Treatment Centers of America - Atlanta
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30265
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Celeste Barker, CCRC
Phone
470-241-7346
Email
celeste.barker@coh.org
First Name & Middle Initial & Last Name & Degree
Herbert L. Duvivier, MD
Facility Name
Emory University Winship Cancer Institute
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Suzanne Scott
Phone
404-778-4083
Email
suzanne.e.scott@emory.edu
First Name & Middle Initial & Last Name & Degree
Olatunji Alese, MD
Facility Name
Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31405
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smith, RN, MSN, OCN
Phone
912-819-5723
Email
smiths1@sjchs.org
First Name & Middle Initial & Last Name & Degree
Mark Taylor, MD
Facility Name
Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31405
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smith, RN, MSN, OCN
Phone
912-819-5723
Email
smiths1@sjchs.org
First Name & Middle Initial & Last Name & Degree
Mark Taylor, MD
Facility Name
Lewis Cancer & Research Pavilion
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31405
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smith, RN, MSN, OCN
Phone
912-819-5723
Email
smiths1@sjchs.org
First Name & Middle Initial & Last Name & Degree
Mark Taylor, MD
Facility Name
Summit Cancer Care
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31405
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smith, RN, MSN, OCN
Phone
912-819-5723
Email
smiths1@sjchs.org
First Name & Middle Initial & Last Name & Degree
Mark Taylor, MD
Facility Name
The Queen's Medical Center (The University of Texas MD Anderson Cancer Center)
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96813
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Cancer Treatment Centers of America-Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60099
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Office of Clinical Trials
Phone
847-731-1777
Email
mrmcresearch@ctca-hope.ocm
First Name & Middle Initial & Last Name & Degree
Eugene Ahn, MD
Facility Name
Community Health Network (The University of Texas MD Anderson Cancer Center)
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46250
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Eckert, MPH
Phone
713-745-8074
Email
ACEckert@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Funda Meric-Bernstam, MD
Facility Name
Harold Alfond Center for Cancer Care
City
Augusta
State/Province
Maine
ZIP/Postal Code
04330
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sandra Neptune, BSN, RN
Phone
207-626-4811
Email
sandra.neptune@mainegeneral.org
First Name & Middle Initial & Last Name & Degree
Lindsay Hathaway, MD
Facility Name
Jackson Laboratory - Maine Cancer Genomics Initiative
City
Augusta
State/Province
Maine
ZIP/Postal Code
04330
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Petra Helbig, CCRP
Phone
207-664-4659
Email
Petra.Helbig@jax.org
First Name & Middle Initial & Last Name & Degree
Jens Rueter, MD
Facility Name
Waldo County General Hospital
City
Belfast
State/Province
Maine
ZIP/Postal Code
04915
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton, MHA, BSN, RN
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
SMHC Cancer Care and Blood Disorders -Biddeford
City
Biddeford
State/Province
Maine
ZIP/Postal Code
04005
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
Northern Light Cancer Care
City
Brewer
State/Province
Maine
ZIP/Postal Code
04412
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carla Mancini, MHA, BSN, RN
Phone
207-973-5581
Email
cmancini@northernlight.org
First Name & Middle Initial & Last Name & Degree
Sarah Sinclair, MD
Facility Name
Raish Peavey Haskell Children's Cancer and Treatment Center
City
Brewer
State/Province
Maine
ZIP/Postal Code
04412
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carla C Mancini, RN, BSN, OCN
Phone
207-973-5581
Email
cmancini@northernlight.org
First Name & Middle Initial & Last Name & Degree
Sarah Sinclair, MD
Facility Name
MaineHealth Cancer Care -Brunswick
City
Brunswick
State/Province
Maine
ZIP/Postal Code
04011
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton, MHA, BSN, RN
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
New England Cancer Specialist
City
Kennebunk
State/Province
Maine
ZIP/Postal Code
04043
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patricia C Collins
Phone
207-303-3422
Email
collip@newecs.org
First Name & Middle Initial & Last Name & Degree
Christian Thomas, MD
Facility Name
York Hopsital Oncology & Infusion Care in Kittery
City
Kittery
State/Province
Maine
ZIP/Postal Code
03904
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brenda i Kiberd, RN
Phone
207-361-6115
Email
Brenda.Kiberd@yorkhospital.com
First Name & Middle Initial & Last Name & Degree
Marilyn McLaughlin, MD
Facility Name
Stephens Memorial Hospital
City
Norway
State/Province
Maine
ZIP/Postal Code
04268
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton, MHA, BSN, RN
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
Penobscot Bay Medical Center
City
Rockport
State/Province
Maine
ZIP/Postal Code
04856
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton, MHA, BSN, RN
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
SMHC Cancer Care and Blood Disorders -Sandford
City
Sanford
State/Province
Maine
ZIP/Postal Code
04073
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton, MHA, BSN, RN
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
Maine Children's Cancer Program
City
Scarborough
State/Province
Maine
ZIP/Postal Code
04074
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton, MHA, BSN, RN
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
Maine Medical Partner's Women's Health
City
Scarborough
State/Province
Maine
ZIP/Postal Code
04074
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton, MHA, BSN, RN
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
New England Cancer Specialist
City
Scarborough
State/Province
Maine
ZIP/Postal Code
04074
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patricia Collins, BA, CCRC
Phone
207-303-3422
Email
collip@newecs.org
First Name & Middle Initial & Last Name & Degree
Christian Thomas, MD
Facility Name
MaineHealth Cancer Care -South Portland
City
South Portland
State/Province
Maine
ZIP/Postal Code
04106
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jen Dalton, MHA, BSN, RN
Phone
207-294-8291
Email
JDalton@mmc.org
First Name & Middle Initial & Last Name & Degree
Roger Inhorn, MD
Facility Name
New England Cancer Specialist
City
Topsham
State/Province
Maine
ZIP/Postal Code
04086
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patricia C Collins, BA, CCRC
Phone
207-303-3422
Email
collip@newecs.org
First Name & Middle Initial & Last Name & Degree
Christian Thomas, MD
Facility Name
York Hospital Oncology & Infusion Care in Wells
City
Wells
State/Province
Maine
ZIP/Postal Code
04090
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brenda Kiberd, RN
Phone
207-361-6115
Email
Brenda.Kiberd@yorkhospital.com
First Name & Middle Initial & Last Name & Degree
Marilyn McLaughlin, MD
Facility Name
York Hospital Oncology & Infusion Care in York
City
York
State/Province
Maine
ZIP/Postal Code
03909
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brenda i Kiberd, RN
Phone
207-361-6115
Email
Brenda.Kiberd@yorkhospital.com
First Name & Middle Initial & Last Name & Degree
Marilyn McLaughlin, MD
Facility Name
Trinity Health Ann Arbor Hospital
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-7251
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Elie Dib, MD
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cancer AnswerLine Nurses
Phone
800-865-1125
Email
canceranswerline@med.umich.edu
First Name & Middle Initial & Last Name & Degree
Ajja Alva, MBBS
Facility Name
Ascension St. John Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48236
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-3671
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Carrie Dul, MD
Facility Name
Genesys Hurley Cancer Institute
City
Grand Blanc
State/Province
Michigan
ZIP/Postal Code
48439
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-3671
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Paul Adams, MD
Facility Name
Cancer Research Consortium of West Michigan
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Connie Szczepanek, RN
Phone
616-391-1230
Email
crcwm-regulatory@crcwm.org
First Name & Middle Initial & Last Name & Degree
Kathleen J. Yost, MD
Facility Name
Sparrow Hospital
City
Lansing
State/Province
Michigan
ZIP/Postal Code
48912
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-3671
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Gordan Srkalovic, MD
Facility Name
Trinity Health Livonia Hospital
City
Livonia
State/Province
Michigan
ZIP/Postal Code
48154
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-7251
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Amit Mohindra, MD
Facility Name
Trinity Health Oakland Hospital
City
Pontiac
State/Province
Michigan
ZIP/Postal Code
48341
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-3671
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Julie Goodman, MD
Facility Name
Ascension St. Mary's Hospital
City
Saginaw
State/Province
Michigan
ZIP/Postal Code
48601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-3671
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Nicholas Damico, MD
Facility Name
Michigan Cancer Research Consortium
City
Traverse City
State/Province
Michigan
ZIP/Postal Code
48341
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Beth LaVasseur, RN, MS
Phone
734-712-7251
Email
Beth.LaVasseur@stjoeshealth.org
Phone
877-590-5995
First Name & Middle Initial & Last Name & Degree
Philip Stella, MD
Facility Name
St. John Macomb Oakland Hospital
City
Warren
State/Province
Michigan
ZIP/Postal Code
48093
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-3671
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Carrie Dul, MD
Facility Name
University of Nebraska Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68198
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tanette Welsh
Phone
402-552-3594
Email
tanette.welsh@unmc.edu
First Name & Middle Initial & Last Name & Degree
Alissa Marr, MD
Facility Name
NH Oncology - Hematology, PA
City
Concord
State/Province
New Hampshire
ZIP/Postal Code
03103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ali Fleury
Phone
603-314-6888
Email
A.Fleury@nhoh.com
First Name & Middle Initial & Last Name & Degree
Douglas Weckstein, MD
Facility Name
Solinsky Center for Cancer Care
City
Manchester
State/Province
New Hampshire
ZIP/Postal Code
03103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ali Fleury, BA, CCRP
Phone
603-314-6888
Email
A.Fleury@nhoh.com
First Name & Middle Initial & Last Name & Degree
Douglas Weckstein, MD
Facility Name
New England Cancer Specialist
City
Portsmouth
State/Province
New Hampshire
ZIP/Postal Code
03801
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patricia C Collins, BA, CCRC
Phone
207-303-3422
Email
collip@newecs.org
First Name & Middle Initial & Last Name & Degree
Christian Thomas, MD
Facility Name
Lovelace Medical Center - Saint Joseph Square
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87102
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leslie Byatt
Phone
505-925-0366
Email
lpbyatt@salud.unm.edu
First Name & Middle Initial & Last Name & Degree
Bernard Tawfik, MD
Facility Name
Presbyterian Kaseman Hospital
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monique Robertson, RN
Phone
505-559-6100
Email
mrobertso2@phs.org
First Name & Middle Initial & Last Name & Degree
Bernard Tawfik, MD
Facility Name
The University of New Mexico Comprehensive Cancer Center
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kawryn Gustafson, RN
Phone
505-925-0380
Email
ksgustafson@salud.unm.edu
First Name & Middle Initial & Last Name & Degree
Bernard Tawfik, MD
Facility Name
Memorial Medical Center
City
Las Cruces
State/Province
New Mexico
ZIP/Postal Code
88011
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kim Hoffman, RN
Phone
575-556-6545
Email
kim.hoffman@lpnt.net
First Name & Middle Initial & Last Name & Degree
Bernard Tawfik, MD
Facility Name
Presbyterian Rust Medical Center
City
Rio Rancho
State/Province
New Mexico
ZIP/Postal Code
87124
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Yost
Phone
505-253-7878
Email
ayost3@phs.org
First Name & Middle Initial & Last Name & Degree
Bernard Tawfik, MD
Facility Name
Northwell Health Monter Cancer Center
City
Lake Success
State/Province
New York
ZIP/Postal Code
11042
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mary Agnes Templeton
Phone
516-734-8979
Email
mtempleton@northwell.edu
First Name & Middle Initial & Last Name & Degree
Marina Frimer, MD
Facility Name
Cohen Children's Medical Center
City
New Hyde Park
State/Province
New York
ZIP/Postal Code
11040
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shreya Seepersaud
Phone
718-470-7146
Email
sseepersaud2@northwell.edu
First Name & Middle Initial & Last Name & Degree
Marina Frimer, MD
Facility Name
Herbert Irving Comprehensive Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kim Roman
Phone
212-342-3970
Email
Lr2787@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Alexander Wei, MD
Facility Name
Manhattan Eye, Ear, and Throat Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leila Nasr
Email
lnasr@northwell.edu
First Name & Middle Initial & Last Name & Degree
Marina Frimer, MD
Facility Name
Phelps Hospital
City
Sleepy Hollow
State/Province
New York
ZIP/Postal Code
10591
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Turner, RN
Phone
914-269-1949
Email
Bturner1@northwell.edu
First Name & Middle Initial & Last Name & Degree
Shyrley Gomez
Email
Sgomez21@northwell.edu
First Name & Middle Initial & Last Name & Degree
Marina Frimer, MD
Facility Name
Lineberger Comprehensive Cancer Center
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emmie Cole
Phone
919-966-4432
Email
emmie_cole@med.unc.edu
First Name & Middle Initial & Last Name & Degree
Shetal Patel, MD
Facility Name
Atrium Health's Levine Cancer Institute
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28277
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kelly Bumgarner, RN, CCRP
Phone
980-521-8696
Email
Kelly.Bumgarner@atriumhealth.org
First Name & Middle Initial & Last Name & Degree
Kathryn F. Mileham, MD, FACP
Facility Name
Sanford Health- Bismarck
City
Bismarck
State/Province
North Dakota
ZIP/Postal Code
58501
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Kurniali, MD
Phone
701-323-5741
Email
peter.kurniali@sanfordhealth.org
First Name & Middle Initial & Last Name & Degree
Peter Kurniali, MD
Facility Name
Sanford Health- Fargo
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58122
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anu Gaba, MD
Phone
701-234-6161
Email
anu.gaba@sanfordhealth.org
First Name & Middle Initial & Last Name & Degree
Anu Gaba, MD
Facility Name
University of Cincinnati Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kayla Webb, MSN, RN
Phone
513-584-0599
Email
webb2ka@ucmail.uc.edu
First Name & Middle Initial & Last Name & Degree
Trisha Wise-Draper, MD
Facility Name
Kettering Health
City
Kettering
State/Province
Ohio
ZIP/Postal Code
45429
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Allison Dymacek, BSN, RN
Phone
937-395-8367
Email
allison.dymacek@ketteringhealth.org
First Name & Middle Initial & Last Name & Degree
Malek Safa, MD
Facility Name
West Chester Hospital
City
West Chester
State/Province
Ohio
ZIP/Postal Code
45069
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kayla Webb, MSN, RN
Phone
513-584-0599
Email
webb2ka@ucmail.uc.edu
First Name & Middle Initial & Last Name & Degree
Trisha Wise-Draper, MD
Facility Name
Providence Health & Services
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isa Ngirailemesang
Phone
971-358-2056
Email
Isa.Ngirailemesang@providence.org
First Name & Middle Initial & Last Name & Degree
Walter Urba, MD
Facility Name
Lehigh Valley Health Network
City
Allentown
State/Province
Pennsylvania
ZIP/Postal Code
18103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-3671
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Maged Khalil, MD
Facility Name
Lehigh Valley Hospital- Muhlenberg
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18017
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-7251
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Maged Khalil, MD
Facility Name
Pocono Medical Center
City
East Stroudsburg
State/Province
Pennsylvania
ZIP/Postal Code
18301
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-7251
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Maged Khalil, MD
Facility Name
Lehigh Valley Hospital-Hazleton
City
Hazleton
State/Province
Pennsylvania
ZIP/Postal Code
18201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
734-712-7251
Email
MCRCwebsitecontactform@trinity-health.org
First Name & Middle Initial & Last Name & Degree
Maged Khalil, MD
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fathima S Sheriff
Phone
215-728-4094
Email
fathima.sheriff@fccc.edu
First Name & Middle Initial & Last Name & Degree
Margaret von Mehren, MD
Facility Name
SC Cancer Specialists at St. Joseph's/Candler Bluffton
City
Bluffton
State/Province
South Carolina
ZIP/Postal Code
29910
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smith, RN, MSN, OCN
Phone
912-819-5723
Email
smiths1@sjchs.org
First Name & Middle Initial & Last Name & Degree
Mark Taylor, MD
Facility Name
St. Joseph's/Candler Smith
City
Bluffton
State/Province
South Carolina
ZIP/Postal Code
29910
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smith, RN, MSN, OCN
Phone
912-819-5723
Email
smiths1@sjchs.org
First Name & Middle Initial & Last Name & Degree
Mark Taylor, MD
Facility Name
Summit Cancer Care at St. Josph's/Candler Bluffton
City
Bluffton
State/Province
South Carolina
ZIP/Postal Code
29910
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smith, RN, MSN, OCN
Phone
912-819-5723
Email
smiths1@sjchs.org
First Name & Middle Initial & Last Name & Degree
Mark Taylor, MD
Facility Name
South Carolina Cancer Specialists
City
Hilton Head Island
State/Province
South Carolina
ZIP/Postal Code
29926
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Smith, RN, MSN, OCN
Phone
912-819-5723
Email
smiths1@sjchs.org
First Name & Middle Initial & Last Name & Degree
Mark Taylor, MD
Facility Name
Sanford Cancer Center Oncology Clinic and Pharmacy
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Powell, MD
Phone
605-328-8000
Email
steven.powell@sanfordhealth.org
First Name & Middle Initial & Last Name & Degree
Steven Powell, MD
Facility Name
Tennessee Oncology - Nashville / Sarah Cannon Research Institute
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ethan Trull
Phone
615-329-7274
Email
Ethan.Trull@SarahCannon.com
First Name & Middle Initial & Last Name & Degree
Meredith McKean, MD, MPH
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amanda Eckert, MPH
Phone
713-745-8074
Email
ACEckert@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Funda Meric-Bernstam, MD
Facility Name
Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
City
Cedar City
State/Province
Utah
ZIP/Postal Code
84720
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jake Kolu
Phone
435-705-1632
Email
Jake.Kolu@imail.org
First Name & Middle Initial & Last Name & Degree
Ramya Thota, MD
First Name & Middle Initial & Last Name & Degree
Derrick Haslem, MD
Facility Name
Dixie Regional Medical Center-River Road Campus
City
Saint George
State/Province
Utah
ZIP/Postal Code
84770
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jake Kolu
Phone
435-705-1632
Email
Jake.Kolu@imail.org
First Name & Middle Initial & Last Name & Degree
Ramya Thota, MD
First Name & Middle Initial & Last Name & Degree
Derrick Haslem, MD
Facility Name
Intermountain Healthcare
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tracy Taylor
Phone
801-507-3953
Email
tracy.taylor@imail.org
First Name & Middle Initial & Last Name & Degree
Ramya Thota, M.D.
First Name & Middle Initial & Last Name & Degree
Derrick Haslem, M.D.
Facility Name
Inova Schar Cancer Institute
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22042
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roxana Comfort, CRC
Phone
571-472-0628
Email
roxana.comfort@inova.org
First Name & Middle Initial & Last Name & Degree
Timothy Cannon, MD
Facility Name
Swedish Cancer Institute
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kim Reeves
Phone
206-337-3851
Email
Kimberly.Reeves@swedish.org
First Name & Middle Initial & Last Name & Degree
Philip Gold, MD
Facility Name
Aurora Cancer Care - Burlington
City
Burlington
State/Province
Wisconsin
ZIP/Postal Code
53105
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Health Care - Germantown Health Center
City
Germantown
State/Province
Wisconsin
ZIP/Postal Code
53022
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Cancer Care - Grafton
City
Grafton
State/Province
Wisconsin
ZIP/Postal Code
53024
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora BayCare Medical Center
City
Green Bay
State/Province
Wisconsin
ZIP/Postal Code
54311
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Cancer Care - Kenosha South
City
Kenosha
State/Province
Wisconsin
ZIP/Postal Code
53142
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Bay Area Medical Center
City
Marinette
State/Province
Wisconsin
ZIP/Postal Code
54143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Cancer Care Milwaukee
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53209
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle M Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora St. Luke's Medical Center
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle M Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Sinai Medical Center
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53223
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora West Allis Medical Center
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53227
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Vince Lombardi Cancer Clinic - Oshkosh
City
Oshkosh
State/Province
Wisconsin
ZIP/Postal Code
54904
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Cancer Care - Racine
City
Racine
State/Province
Wisconsin
ZIP/Postal Code
53406
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Vince Lombardi Cancer Center
City
Sheboygan
State/Province
Wisconsin
ZIP/Postal Code
53081
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Medical Center in Summit
City
Summit
State/Province
Wisconsin
ZIP/Postal Code
53066
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Vince Lombardi Cancer Clinic - Two Rivers
City
Two Rivers
State/Province
Wisconsin
ZIP/Postal Code
54241
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
Facility Name
Aurora Cancer Care - Milwaukee West
City
Wauwatosa
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michelle Toutloff, RN, CCRP
Phone
920-456-7880
Email
Michelle.Martin2@aah.org
First Name & Middle Initial & Last Name & Degree
Antony Ruggeri, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
36315917
Citation
Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
Results Reference
derived
PubMed Identifier
33844595
Citation
Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
Results Reference
derived
PubMed Identifier
33090333
Citation
Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
Results Reference
derived
PubMed Identifier
33068284
Citation
Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
Results Reference
derived
Learn more about this trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
We'll reach out to this number within 24 hrs